Study to compare the bioavailability of ABT-335 [choline fenofibrate] and rosuvastatin from ABT-143 [rosuvastatin/choline fenofibrate] relative to that from the co-administration of ABT-335 and rosuvastatin calcium

Trial Profile

Study to compare the bioavailability of ABT-335 [choline fenofibrate] and rosuvastatin from ABT-143 [rosuvastatin/choline fenofibrate] relative to that from the co-administration of ABT-335 and rosuvastatin calcium

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Sep 2012

At a glance

  • Drugs Choline fenofibrate; Rosuvastatin; Rosuvastatin/choline fenofibrate
  • Indications Hyperlipidaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 14 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Oct 2010 Actual end date (August 2008) added as reported by ClinicalTrials.gov.
    • 10 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top